Global Liver Disease Cases Soar to 1.3 Billion, Projected to Hit 1.8 Billion by 2050

A landmark analysis published in The Lancet Gastroenterology & Hepatology journal reveals a startling increase in the global burden of Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). The study, drawing on data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, estimates that approximately 1.3 billion people worldwide were living with MASLD in 2023. This figure represents a staggering 143 percent increase in crude numbers since 1990, underscoring the rapid and widespread nature of this chronic liver disorder. The projections for the coming decades are even more concerning. Researchers forecast that the global number of MASLD cases could surge to nearly 1.8 billion by 2050. This anticipated rise, a 42 percent increase from 2023 levels, is predominantly driven by factors such as global population growth, coupled with evolving lifestyle patterns. Key contributors to this escalating prevalence include increasing rates of obesity, high blood sugar levels, and increasingly sedentary behaviors associated with urbanization. High blood sugar, high BMI, and smoking were identified as leading drivers of MASLD-related health problems globally. The study highlights that MASLD is no longer solely a concern for older demographics. It is increasingly affecting younger adults, particularly in low- and middle-income countries, where rapid urbanization, dietary shifts, and reduced physical activity are accelerating the spread of metabolic disorders. Geographically, regions like North Africa and the Middle East exhibited disproportionately higher age-standardized prevalence rates of MASLD compared to other areas, being more than three times higher than those observed in high-income Asia Pacific regions. Despite the sharp increase in the number of cases, the overall impact on health—measured in years lost due to illness or death (DALYs)—has remained relatively stable. This suggests that advances in early diagnosis, treatment, and disease management may be enabling people to live longer and healthier with the condition, with the increase largely occurring in the early stages of the disease. However, experts caution that this growing pool of affected individuals still presents a significant risk, as many could progress to severe complications such as liver cirrhosis or liver cancer in the future. MASLD is also linked to an increased risk of type 2 diabetes and cardiovascular disease, making it a broader metabolic health concern. For India, the implications are particularly significant. The country has demonstrated a sharp rise in MASLD prevalence, with an increase of 23.19 percent from 1990 to 2023. This makes MASLD a major metabolic health crisis in India, driven by factors mirroring global trends like rising obesity, diabetes, and sedentary lifestyles. Experts in India emphasize the need for early screening, metabolic control, and sustained lifestyle changes, warning that delayed action will exacerbate the burden of liver, cardiovascular, and other metabolic complications. The findings underscore the critical importance of recognizing MASLD as a global health priority. Researchers and medical professionals are calling for dedicated policies, increased public awareness campaigns, and robust interventions to mitigate its escalating impact and prevent future complications. Urgent action is needed to integrate chronic liver diseases into global health strategies, with proposals including routine screening for at-risk groups, incorporating liver testing into regular health check-ups, and updating reimbursement policies to facilitate broader access to care. Effective treatments must be coupled with improved diagnostic access to truly address this growing public health threat. Beyond MASLD, it is important to note that other forms of liver disease, such as alcohol-associated liver disease and viral hepatitis, also contribute substantially to the global burden of liver conditions. While the incidence of viral hepatitis has seen some decline in certain regions, alcohol-related liver cirrhosis deaths have risen, and drug-induced liver injury continues to increase. However, MASLD's rapid growth makes it a particularly pressing issue, highlighting the need for a multi-faceted approach to liver health globally. In summary, the Lancet report serves as a stark warning about the rapidly expanding prevalence of MASLD worldwide. With cases projected to reach 1.8 billion by 2050, largely due to preventable lifestyle factors, the urgency for comprehensive public health strategies, early intervention, and widespread awareness campaigns has never been greater, particularly for countries like India facing a substantial increase in affected populations.

Frequently Asked Questions

Read Full Story on Quick Digest